Capsid Inhibitors

Arbutus is currently evaluating capsid inhibitors for the treatment of chronic HBV infection. By inhibiting assembly of the viral capsid, capsid inhibitors effectively block viral replication.


We have a number of oral capsid inhibitor compounds with distinct chemical scaffolds that we believe have the potential to contribute to the inhibition of HBV replication as part of a combination regimen.


Our objective is to select one of several lead compounds for IND-enabling studies by December 2019.